IP Library Granted Patent US 11,161,902
Granted Patent B2
US 11,161,902 · App. 16/300,019 · Granted Nov 2, 2021

Tissue-specific exosomes as biomarkers

Inventors: Kerstin Stemmer (Munich, DE); Matthias Tschöp (Munich, DE); Michaela Bauer (Landshut, DE); Reinhard Zeidler (Olching, DE); Regina Feederle (Munich, DE)
Assignee: Helmholtz Zentrum Muenchen—Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (GmbH)
C07K16/28G01N33/6893G01N2800/04G01N2800/042G01N2800/044
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,161,902
App. No.
16/300,019
Granted
Nov 2, 2021
Kind
B2
Abstract

In general, the present invention relates to the field of (bio-)medicine and in particular to various metabolic diseases. Specifically, the invention provides means and methods for diagnosing, monitoring and predicting the risk for developing metabolic diseases. The invention uses exosomes as biomarkers for the aforementioned purposes. Moreover, an antibody of the present invention capable of specifically recognizing tissue-specific exosomes is also provided.

Claims (12)

1. An antibody capable of specifically binding to a tissue-specific exosomal surface marker, wherein said antibody comprises

a) VH and VL domain CDRs comprising the amino acid sequences SEQ ID Nos. 1 to 3 and 4 to 6;

b) VH and VL domain CDRs comprising the amino acid sequences SEQ ID Nos. 7 to 9 and 10 to 12; or

c) VH and VL domain CDRs comprising the amino acid sequences SEQ ID Nos. 13 to 15 and 16 to 18.

2. A kit comprising a reagent for detecting the presence of a tissue-specific exosomal surface marker and for isolating tissue-specific exosomes from a sample of a subject, wherein said reagent comprises an antibody capable of specifically binding to said tissue-specific exosomal surface marker, wherein said antibody comprises

a) VH and VL domain CDRs comprising the amino acid sequences SEQ ID Nos. 1 to 3 and 4 to 6;

b) VH and VL domain CDRs comprising the amino acid sequences SEQ ID Nos. 7 to 9 and 10 to 12; or

c) VH and VL domain CDRs comprising the amino acid sequences SEQ ID Nos. 13 to 15 and 16 to 18.

3. A composition comprising the antibody of claim 1 and a biological sample comprising tissue-specific exosome.

4. The composition of claim 3 , wherein the biological sample is selected from the group consisting of a blood sample, a plasma sample, a serum sample, lymph, saliva, bile, feces, breast milk, a urine sample, a cerebrospinal fluid sample, amniotic fluid, and an organ or tissue biopsy sample.

5. A method for isolating a tissue-specific exosome comprising obtaining the composition of claim 3 , and isolating tissue-specific exosomes using the antibody.

6. The method of claim 5 , further comprising a step of detecting the tissue-specific exosomes that are isolated using the antibody.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 31, 2018
From: STEMMER, KERSTIN; TSCHOP, MATTHIAS; BAUER, MICHAELA; ZEIDLER, REINHARD; FEEDERLE, REGINA
To: HELMHOLTZ ZENTRUM MUNCHEN - DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH)
Reel/Frame 047877/0460 →
Priority Claims (1)
LU 93058 · May 9, 2016 · national
Continuity (1)
Related Publication 20190391163A1 · Dec 26, 2019